PURPOSE: The aim of this study was to determine the efficacy and safety of docetaxel plus epirubicin combination as first-line chemotherapy in patients with locally advanced and/or metastatic adult STS. PATIENTS AND METHODS: Eighteen patients were treated with epirubicin 30 mg/m(2) on days 1 to 3 and docetaxel 100 mg/m(2) on day 1 every 3 weeks. RESULTS: Fifteen out of 18 patients (83.4%) were assessable for response. No complete response was recorded. Three (20%) patients achieved PR, 3 had SD and 9 PD. The overall median survival was 14 months (range, 3-48 months) and the median time to disease progression was 4 months (range, 2-45 months). Grade >/= 3 neutropenia occurred in 88% and neutropenic fever in 27.8% of patients. Other toxicities were mild. No treatment related deaths occurred. DISCUSSION: Docetaxel plus epirubicin combination achieved low response rate with severe myelotoxicity in patients with advanced STS.
PURPOSE: The aim of this study was to determine the efficacy and safety of docetaxel plus epirubicin combination as first-line chemotherapy in patients with locally advanced and/or metastatic adult STS. PATIENTS AND METHODS: Eighteen patients were treated with epirubicin 30 mg/m(2) on days 1 to 3 and docetaxel 100 mg/m(2) on day 1 every 3 weeks. RESULTS: Fifteen out of 18 patients (83.4%) were assessable for response. No complete response was recorded. Three (20%) patients achieved PR, 3 had SD and 9 PD. The overall median survival was 14 months (range, 3-48 months) and the median time to disease progression was 4 months (range, 2-45 months). Grade >/= 3 neutropenia occurred in 88% and neutropenic fever in 27.8% of patients. Other toxicities were mild. No treatment related deaths occurred. DISCUSSION: Docetaxel plus epirubicin combination achieved low response rate with severe myelotoxicity in patients with advanced STS.
Authors: M Van Glabbeke; A T van Oosterom; J W Oosterhuis; H Mouridsen; D Crowther; R Somers; J Verweij; A Santoro; J Buesa; T Tursz Journal: J Clin Oncol Date: 1999-01 Impact factor: 44.544
Authors: R Palumbo; C Neumaier; M Cosso; G Bertero; P Raffo; N Spadini; S Valente; G Villani; M Pastorino; S Toma Journal: Eur J Cancer Date: 1999-01 Impact factor: 9.162
Authors: J Verweij; S M Lee; W Ruka; J Buesa; R Coleman; R van Hoessel; C Seynaeve; E D di Paola; M van Glabbeke; D Tonelli; I R Judson Journal: J Clin Oncol Date: 2000-05 Impact factor: 44.544
Authors: O S Nielsen; P Dombernowsky; H Mouridsen; D Crowther; J Verweij; J Buesa; W Steward; S Daugaard; M van Glabbeke; A Kirkpatrick; T Tursz Journal: Br J Cancer Date: 1998-12 Impact factor: 7.640